Skip to content
Study details
Enrolling now

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Rise Therapeutics LLC
NCT IDNCT05666960ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

36

Study length

about 2.7 years

Ages

18–65

Locations

4 sites in CA, FL, MN

What this study is about

This trial is testing the safety and tolerability of R-3750, an oral probiotic, in people with mild to moderate ulcerative colitis. Participants will take R-3750 orally and provide information about their condition through patient reports and doctor evaluations. Blood and stool tests will also be done to measure inflammation and assess R-3750 levels in the gut.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take R-3750

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug routes

oral

Endpoints

Primary: To assess the tolerability of R-3750

Body systems

Gastroenterology